Bristol-Myers Squibb Company and Pfizer Inc. Data on ELIQUIS® (apixaban) for the Prevention of Stroke in Atrial Fibrillation to be Presented at American College of Cardiology’s 61st Annual Scientific Session

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced additional analyses from the ARISTOTLE and AVERROES clinical trials will be presented at the American College of Cardiology’s 61st Annual Scientific Session, March 24-27, 2012, in Chicago. The two large Phase 3 clinical trials compared ELIQUIS® (apixaban), an investigational compound for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, with warfarin and aspirin, respectively.